Subscribe
aleksandar-mijatovic-shutterstock-com-2
Aleksandar Mijatovic / Shutterstock.com
16 September 2015Asia

Indian Pharmaceutical Alliance drops Sovaldi opposition

The Indian Pharmaceutical Alliance (IPA) has dropped its opposition to a patent application filed by Gilead Sciences covering its hepatitis C drug Sovaldi (sofosbuvir).

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Asia-Pacific
Gilead gets Sovaldi patent approval in India despite opposition
10 May 2016   Gilead has been granted a patent for its hepatitis C drug Sovaldi in India, despite concerns over the cost of the drug.
Asia
Indian drug makers end generic bids
18 April 2016   Indian-based drugs companies BDR Pharmaceutical and Lee Pharmaceutical have reportedly abandoned their attempt to produce generic versions of two drugs developed by AstraZeneca and Bristol-Myers Squibb.
Americas
Gilead faces fresh Sovaldi challenge
20 May 2015   Gilead Sciences is facing a challenge to its attempt to obtain a patent for its hepatitis C drug Sovaldi in certain Asian, Latin American and European countries.


Editor's picks

Life sciences leaders recognised at LSPN Awards USA 2025
Americas
Life sciences leaders recognised at LSPN Awards USA 2025
8 May 2025

Editor's picks

Americas
Life sciences leaders recognised at LSPN Awards USA 2025
8 May 2025
Americas
LSPN: Using ‘the patentee’s friend’ in Section 112 claims
6 May 2025
Americas
Why US patent reform is ‘essential’ for US economic prosperity and security
29 April 2025
Europe
Meril v Edwards: Harmonisation of obviousness at the UPC and the EPO
24 April 2025
Americas
WIPR Diversity & Inclusion reveals Top 100 People in IP for 2025
24 April 2025
Big Pharma
AstraZeneca unit faces class-action suit over alleged Soliris monopoly
17 April 2025

More on this story

Asia-Pacific
Gilead gets Sovaldi patent approval in India despite opposition
10 May 2016   Gilead has been granted a patent for its hepatitis C drug Sovaldi in India, despite concerns over the cost of the drug.
Asia
Indian drug makers end generic bids
18 April 2016   Indian-based drugs companies BDR Pharmaceutical and Lee Pharmaceutical have reportedly abandoned their attempt to produce generic versions of two drugs developed by AstraZeneca and Bristol-Myers Squibb.
Americas
Gilead faces fresh Sovaldi challenge
20 May 2015   Gilead Sciences is facing a challenge to its attempt to obtain a patent for its hepatitis C drug Sovaldi in certain Asian, Latin American and European countries.

More on this story

Asia-Pacific
Gilead gets Sovaldi patent approval in India despite opposition
10 May 2016   Gilead has been granted a patent for its hepatitis C drug Sovaldi in India, despite concerns over the cost of the drug.
Asia
Indian drug makers end generic bids
18 April 2016   Indian-based drugs companies BDR Pharmaceutical and Lee Pharmaceutical have reportedly abandoned their attempt to produce generic versions of two drugs developed by AstraZeneca and Bristol-Myers Squibb.
Americas
Gilead faces fresh Sovaldi challenge
20 May 2015   Gilead Sciences is facing a challenge to its attempt to obtain a patent for its hepatitis C drug Sovaldi in certain Asian, Latin American and European countries.

More features

Life sciences leaders recognised at LSPN Awards USA 2025
UK-India trade deal is ‘a missed opportunity for UK pharma’, says industry body
LSPN: Counsel grapple with AI’s impact on training and critical thinking
'Nothing can stand in the way of our work': Ukraine resumes IP system
LSPN: Trump's policy storm causing chaos and confusion
Taylor Wessing expands in Europe with Paris team
LSPN: Using ‘the patentee’s friend’ in Section 112 claims
ResMed voids sleep apnoea tech patent at PTAB